OrphAI Therapeutics is advancing the following drugs into clinical trials/development: LAM-001 for Group 1 and Group 3 Pulmonary Hypertension (PH) and Bronchiolitis Obliterans Syndrome post lung transplant (BOS); AIT-102 for SWI/SNF mutated/dysregulated cancers.